Search Results

Clinical Chemistry - The Sentinel Clin Chem Cal is a device intended for medical purposes for use in Pancreatic amylase, Cholinesterase, Creatinine, Lithium, Alpha-Hydroxybutyrate Dehydrogenase and "Cholinesterase Dibucaine-Inhibited" assays to establish points of reference that are used in the determination of values in the measurement of Pancreatic amylase, Cholinesterase, Creatinine, Lithium, Alpha-Hydroxybutyrate Dehydrogenase and "Cholinesterase Dibucaine-Inhibited" in human specimens.

The Sentinel Clin Chem Cal is a lyophilized Calibrator prepared with human based serum. It consists of 4 x 3 mL bottles of lyophilized material containing pancreatic amylase, cholinesterase Creatinine, Lithium, Alpha-Hydroxybutyrate Dehydrogenase and "Cholinesterase Dibucainedi in a lyophilized human serum matrix. This material is stable until the date printed on the label when stored as directed.

The provided text is a 510(k) summary for the Sentinel Clin Chem Cal, a multiparameter calibrator. It describes modifications to an existing device, adding new analytes. However, it does not contain information about specific acceptance criteria or a study proving the device meets those criteria in the context of typical diagnostic device performance metrics like sensitivity, specificity, or accuracy.

The document focuses on the calibration process for assigning values to the calibrator itself, rather than evaluating the performance of a diagnostic device that uses the calibrator. Therefore, many of the requested categories for a diagnostic device study are not applicable or cannot be extracted from this specific document.

Here's an attempt to answer based only on the provided text, noting where information is absent or not relevant for this type of device:

1. A table of acceptance criteria and the reported device performance

The document describes the process for assigning values to the calibrator analytes and the quality control steps during that assignment process. It doesn't present acceptance criteria for a diagnostic device's performance (e.g., sensitivity, specificity, accuracy).

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is for the calibrator value assignment process, not a diagnostic device's test set.

• Sample Size: 30 randomly selected vials of calibrator material were used for value assignment.
• Data Provenance: Not explicitly stated. The submitter is from Milano, Italy, but the location where the testing was performed is not specified. It's an internal process for calibrator characterization.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

Not applicable. This document describes the process of assigning values to a calibrator using an instrument (Abbott ARCHITECT® c8000 System) and predefined internal protocols. It does not involve human experts establishing ground truth in the context of, for example, image interpretation or clinical diagnosis. Traceability to certified reference materials/organizations (DGKC, IFCC, NIST) is mentioned for the analytes.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. This is not a study involving human interpretation or adjudication. The value assignment process involves calculations of mean, standard deviation, and %CV, with outlier detection, based on instrument readings.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This document is for a chemical calibrator, not an AI-assisted diagnostic device.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This concept doesn't directly apply. The "standalone" performance here refers to the calibrator's assigned values being determined by an automated analytical instrument (Abbott ARCHITECT® c8000 System) following a defined protocol, without human interpretive input for the final value.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

For the calibrator, the "ground truth" (assigned values) is established through a rigorous internal process involving:

• Measurement on a qualified instrument (Abbott ARCHITECT® c8000 System).
• Calibration against an Internal Master Lot.
• Confirmation using control materials.
• Traceability to recognized international and national standards: Deutsche Gesellschaft für Klinische Chemie (DGKC), International Federation of Clinical Chemistry (IFCC), and NIST, SRM 909b.

8. The sample size for the training set

Not applicable. Calibrators are characterized, not "trained" in the machine learning sense. The process described is for determining the values of a batch of calibrators.

9. How the ground truth for the training set was established

Not applicable. As above, there's no "training set." The ground truth for the calibrator's values is established by measuring reconstituted vials on a calibrated instrument against an Internal Master Lot, with traceability to external reference standards, and applying statistical analysis (mean, SD, %CV, outlier detection).

Ask a specific question about this device

The Abbott Aeroset® Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma on the Abbott Aeroset® analyzer (K980367). Monitoring serum phenytoin concentrations, along with careful clinical assessment, is the most effective means of improving seizure control, reducing the risk of toxicity, and minimizing the need for additional anti-convulsant medication for the following reasons:

• Serum phenytoin concentrations correlate better with pharmacologic activity than does . dosage because of individual differences in absorption, metabolism, disease states, concomitant medication, and compliance. Serum concentration monitoring helps physicans individualize dosage regimens.
• The hepatic enzyme system for metabolizing phenytoin can become saturated within the . drug's therapeutic range. When this occurs, small dosage alterations can lead to unexpected drug accumulation and clinical toxicity.
• Phenytoin is safe and effective only in a narrow range of serum concentrations. .
• Methods historically used to monitor serum phenytoin concentrations include . chromatographic assays and immunoassays.

The Abbott Aeroset® Phenytoin Assay is a homogenous enzyme assay intended for use in quantitative analysis of Phenytoin in human serum or plasma.

The Abbott Aeroset Phenytoin Assay device is a homogeneous enzyme immunoassay intended for the quantitative analysis of phenytoin in human serum or plasma.

Here's an analysis of the provided information:

1. Acceptance Criteria and Reported Device Performance

2. Sample Size and Data Provenance

The document does not explicitly state the sample size used for the test set or the data provenance (e.g., country of origin, retrospective/prospective). It only mentions "A Precision study was performed" and "The comparative analysis to the predicate method".

3. Number of Experts and Qualifications

This information is not provided in the document. The nature of this in vitro diagnostic device (quantitative analysis of a chemical compound) typically relies on laboratory measurements and comparison to a predicate device rather than expert interpretation of images or clinical cases.

4. Adjudication Method

This information is not applicable and not provided. Adjudication methods like 2+1 or 3+1 are typically used for studies involving human interpretation of data (e.g., medical images) to establish ground truth from multiple experts. For this device, the performance is based on analytical measurements.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No MRMC study was done. This type of study assesses how AI assistance impacts human reader performance, which is not relevant for a standalone analytical assay like the Abbott Aeroset Phenytoin Assay.

6. Standalone Performance

Yes, a standalone performance was done. The document describes the "Comparative Analysis" and "Precision" studies of the Abbott Aeroset Phenytoin Assay, which represent its performance without human-in-the-loop assistance for the core measurement. The device's output is a quantitative value.

7. Type of Ground Truth Used

The ground truth for the "Comparative Analysis" was the results obtained from the predicate device, Emit® 2000 Phenytoin Assay (K913429). For the "Precision" study, typical ground truth would be based on expected values for control samples or replicate measurements.

8. Sample Size for the Training Set

This information is not provided. For an enzyme immunoassay, the "training set" would typically refer to the data used for assay development, optimization, and calibration curve generation. The document does not detail this.

9. How the Ground Truth for the Training Set Was Established

This information is not provided. For an immunoassay, the training set's ground truth would likely be established through:

• Reference materials: Known concentrations of phenytoin used to create calibration curves.
• Analytical methods: Independent, highly accurate analytical methods (e.g., GC-MS or HPLC) to confirm the concentrations of standards and controls.
• Predicate device results: If the assay was benchmarked against an existing method during development, results from the predicate device would also serve as a form of ground truth for method development.

Ask a specific question about this device

The Abbott Aeroset® Phenobarbital Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenobarbital in human serum or plasma on the Abbott Aeroset® analyzer (K980367). Monitoring serum phenobarbital concentrations, along with careful clinical assessment, is the most effective means of improving seizure control, reducing the risk of toxicity, and minimizing the need for additional anticonvulsant medication for the following reasons (1-3):

• Serum phenobarbital concentrations correlate better with concentration in the brain than does dosage once steady state is reached.
• Patients taking the same dosage of phenobarbital show considerable variation in serum phenobarbital concentrations because of individual differences in absorption, metabolism, disease states, and compliance. Serum level monitoring helps physicians individualize dosage regimens.

Methods historically used to monitor serum phenobarbital concentrations are gas-liquid chromatography, high-performance liquid chromatography, radioimmunoassay, and immunoassay (1,2).

The Abbott Aeroset™ Phenobarbital Assay is a homogenous enzyme assay intended for use in quantitative analysis of phenobarbital in human serum or plasma.

Here's an analysis of the Abbott Aeroset Phenobarbital Assay based on the provided text, outlining the acceptance criteria and the study that proves the device meets those criteria:

1. Table of Acceptance Criteria and Reported Device Performance:

2. Sample Size Used for the Test Set and Data Provenance:

The document does not specify the sample size used for the test set in the comparative analysis or precision studies. It also does not explicitly state the country of origin of the data or whether the study was retrospective or prospective.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications:

The document does not mention the use of experts to establish a ground truth for the test set. The evaluation is based on comparison to a predicate device and internal precision measurements.

4. Adjudication Method for the Test Set:

No adjudication method is mentioned as there were no independent experts establishing ground truth. The comparison is made against the results from a predicate device.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done:

No, an MRMC comparative effectiveness study was not conducted. This device is an in-vitro diagnostic assay, not an imaging or diagnostic interpretation tool that would typically involve multiple human readers.

6. If a Standalone (Algorithm-Only Without Human-in-the-Loop Performance) Was Done:

Yes, the studies described are standalone performance evaluations of the Abbott Aeroset Phenobarbital Assay itself. The "algorithm" here refers to the homogeneous enzyme immunoassay mechanism. The performance metrics (correlation, precision) are directly attributable to the device's function without human interpretation impacting the measurement results.

7. The Type of Ground Truth Used:

The primary "ground truth" used for performance evaluation is the predicate device's measurements (Emit® 2000 Phenobarbital Assay) and the inherent statistical properties of the assay itself (precision). For the comparative analysis, the ground truth is effectively the results obtained from the previously cleared Emit® 2000 Phenobarbital Assay.

8. The Sample Size for the Training Set:

The document does not specify a training set sample size. This type of in-vitro diagnostic assay is typically developed and optimized through validation studies, rather than "training" in the machine learning sense with a distinct training set. The reported studies are performance verification studies.

9. How the Ground Truth for the Training Set Was Established:

As there is no explicitly mentioned "training set" in the machine learning context, there is no description of how ground truth for such a set was established. Development and optimization of the assay would have involved standard analytical chemistry validation practices to ensure accuracy and reliability.

Ask a specific question about this device